Innovation through medical chemistry. Facing the challenges of the adenosine field
It is a laboratory that investigates and develops new drugs to improve the life quality of the people who suffer any neurodegenerative and respiratory diseases. Both companies, everis, Fitalent, and Inveready Seed Capital has invested one million euros in this company
Therefore, Palobiofarma has developed an extensive intellectual property around compounds that modulate the adenosine receptors. After more than five years of research, the company will begin, this year, to conduct clinical trials with an antagonist of A2a adenosine receptor for the treatment of Parkinson’s. this study will be followed by a second product, a potent antagonist of A1 adenosine receptor for oral treatment of asthma, whose trials began the first quarter of 2013.
Visit website
What media say
Reuters
Diario de Navarra
Genengnews
New technologies for drugs and biomaterials stabilization
Computer control technology by eye movement
3D scanning technology that uses structured white light
Test, measurement and control electronic equipment
